Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Clinical and translational advances in ovarian cancer therapy
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …
is initially very responsive to platinum-based chemotherapy. However, the majority of …
[HTML][HTML] The systemic treatment of recurrent ovarian cancer revisited
T Baert, A Ferrero, J Sehouli, DM O'donnell… - Annals of …, 2021 - Elsevier
Highlights•Platinum-based chemotherapy remains the most active treatment for ovarian
cancer.•Platinum should not be withheld after response to last platinum and a treatment-free …
cancer.•Platinum should not be withheld after response to last platinum and a treatment-free …
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Background Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have
shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of …
shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of …
Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study
Purpose: Preclinical studies suggest PARP inhibition (PARPi) induces immunostimulatory
micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade …
micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade …
Advances in the management of peritoneal malignancies
Peritoneal surface malignancies (PSMs) are usually associated with a poor prognosis.
Nonetheless, in line with advances in the management of most abdominopelvic metastatic …
Nonetheless, in line with advances in the management of most abdominopelvic metastatic …
Mfn2-mediated mitochondrial fusion promotes autophagy and suppresses ovarian cancer progression by reducing ROS through AMPK/mTOR/ERK signaling
Mitochondrial dynamics are balanced fission and fusion events that regulate mitochondrial
morphology, and alteration in these events results in mitochondrial dysfunction and …
morphology, and alteration in these events results in mitochondrial dysfunction and …
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based
chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic …
chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic …
[HTML][HTML] Immunotherapies and combination strategies for immuno-oncology
The advent of novel immunotherapies in the treatment of cancers has dramatically changed
the landscape of the oncology field. Recent developments in checkpoint inhibition therapies …
the landscape of the oncology field. Recent developments in checkpoint inhibition therapies …
[HTML][HTML] Therapeutic targeting of DNA damage response in cancer
DNA damage response (DDR) is critical to ensure genome stability, and defects in this
signaling pathway are highly associated with carcinogenesis and tumor progression …
signaling pathway are highly associated with carcinogenesis and tumor progression …
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
Background Response to immune checkpoint blockade (ICB) in ovarian cancer remains
disappointing. Several studies have identified the chemokine CXCL9 as a robust …
disappointing. Several studies have identified the chemokine CXCL9 as a robust …